Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression

Fumio Nakajima, Ashwani Khanna, Guoping Xu, Mila Lagman, Rudy Haschemeyer, Janet Mouradian, John C. Wang, Kurt H. Stenzel, Albert L. Rubin, Manikkam Suthanthiran

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-activated killer cells, has brought new hope to patients with cancer. The broad application of this strategy, however, is constrained by the need for repeated leukapheresis and by the labor-intensive process of in vitro activation of cells. Also, current protocols generally use nonphysiological and toxic concentrations of IL-2. Identification of an in vivo stimulant that renders T cells responsive to physiologic concentrations of IL-2 represents a potential improvement over existing approaches. We have determined whether in vivo administration of monoclonal antibodies (mAbs) directed at the T-cell surface protein CD3 induces T-cell responsiveness to IL-2, stimulates cytolytic molecular programs of natural killer cells and cytotoxic T cells, and induces tumor regression. These hypotheses were explored in a murine hepatic MCA-102 fibrosarcoma model. We report that in vivo administration of anti-CD3 mAbs plus IL-2 results in intrahepatic expression of mRNA-encoding perforin, cytotoxic T-cell-specific serine esterase, and tumor necrosis factor α. Anti-CD3 mAbs alone or IL-2 alone failed to induce or induced minimal expression of these molecular mediators of cytotoxicity. The anti-CD3 mAbs plus IL-2 regimen also resulted in a significantly smaller number of hepatic metastases and a significantly longer survival time of tumor-bearing mice, compared to treatment with anti- CD3 mAbs alone or IL-2 alone. Our findings suggest that a regimen of anti- CD3 mAbs plus IL-2 is a more effective antitumor regimen compared with anti- CD3 mAbs alone or IL-2 alone and advance an alternative immunotherapy strategy of potential value for the treatment of cancer in humans.

Original languageEnglish
Pages (from-to)7889-7893
Number of pages5
JournalProceedings of the National Academy of Sciences of the United States of America
Volume91
Issue number17
DOIs
Publication statusPublished - 16 Aug 1994
Externally publishedYes

Fingerprint

Immunotherapy
Interleukin-2
Monoclonal Antibodies
Neoplasms
T-Lymphocytes
Leukapheresis
Adoptive Immunotherapy
Perforin
Fibrosarcoma
Poisons
Liver
Natural Killer Cells
Membrane Proteins
Tumor Necrosis Factor-alpha
Neoplasm Metastasis
Messenger RNA
Survival
Therapeutics

Keywords

  • antitumor efficacy
  • perforin
  • T-cell signaling

ASJC Scopus subject areas

  • General

Cite this

Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2 : Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. / Nakajima, Fumio; Khanna, Ashwani; Xu, Guoping; Lagman, Mila; Haschemeyer, Rudy; Mouradian, Janet; Wang, John C.; Stenzel, Kurt H.; Rubin, Albert L.; Suthanthiran, Manikkam.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 91, No. 17, 16.08.1994, p. 7889-7893.

Research output: Contribution to journalArticle

Nakajima, Fumio ; Khanna, Ashwani ; Xu, Guoping ; Lagman, Mila ; Haschemeyer, Rudy ; Mouradian, Janet ; Wang, John C. ; Stenzel, Kurt H. ; Rubin, Albert L. ; Suthanthiran, Manikkam. / Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2 : Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression. In: Proceedings of the National Academy of Sciences of the United States of America. 1994 ; Vol. 91, No. 17. pp. 7889-7893.
@article{86c17cf8cd25475dad882ee4e8bcc176,
title = "Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2: Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression",
abstract = "Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-activated killer cells, has brought new hope to patients with cancer. The broad application of this strategy, however, is constrained by the need for repeated leukapheresis and by the labor-intensive process of in vitro activation of cells. Also, current protocols generally use nonphysiological and toxic concentrations of IL-2. Identification of an in vivo stimulant that renders T cells responsive to physiologic concentrations of IL-2 represents a potential improvement over existing approaches. We have determined whether in vivo administration of monoclonal antibodies (mAbs) directed at the T-cell surface protein CD3 induces T-cell responsiveness to IL-2, stimulates cytolytic molecular programs of natural killer cells and cytotoxic T cells, and induces tumor regression. These hypotheses were explored in a murine hepatic MCA-102 fibrosarcoma model. We report that in vivo administration of anti-CD3 mAbs plus IL-2 results in intrahepatic expression of mRNA-encoding perforin, cytotoxic T-cell-specific serine esterase, and tumor necrosis factor α. Anti-CD3 mAbs alone or IL-2 alone failed to induce or induced minimal expression of these molecular mediators of cytotoxicity. The anti-CD3 mAbs plus IL-2 regimen also resulted in a significantly smaller number of hepatic metastases and a significantly longer survival time of tumor-bearing mice, compared to treatment with anti- CD3 mAbs alone or IL-2 alone. Our findings suggest that a regimen of anti- CD3 mAbs plus IL-2 is a more effective antitumor regimen compared with anti- CD3 mAbs alone or IL-2 alone and advance an alternative immunotherapy strategy of potential value for the treatment of cancer in humans.",
keywords = "antitumor efficacy, perforin, T-cell signaling",
author = "Fumio Nakajima and Ashwani Khanna and Guoping Xu and Mila Lagman and Rudy Haschemeyer and Janet Mouradian and Wang, {John C.} and Stenzel, {Kurt H.} and Rubin, {Albert L.} and Manikkam Suthanthiran",
year = "1994",
month = "8",
day = "16",
doi = "10.1073/pnas.91.17.7889",
language = "English",
volume = "91",
pages = "7889--7893",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "17",

}

TY - JOUR

T1 - Immunotherapy with anti-CD3 monoclonal antibodies and recombinant interleukin 2

T2 - Stimulation of molecular programs of cytotoxic killer cells and induction of tumor regression

AU - Nakajima, Fumio

AU - Khanna, Ashwani

AU - Xu, Guoping

AU - Lagman, Mila

AU - Haschemeyer, Rudy

AU - Mouradian, Janet

AU - Wang, John C.

AU - Stenzel, Kurt H.

AU - Rubin, Albert L.

AU - Suthanthiran, Manikkam

PY - 1994/8/16

Y1 - 1994/8/16

N2 - Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-activated killer cells, has brought new hope to patients with cancer. The broad application of this strategy, however, is constrained by the need for repeated leukapheresis and by the labor-intensive process of in vitro activation of cells. Also, current protocols generally use nonphysiological and toxic concentrations of IL-2. Identification of an in vivo stimulant that renders T cells responsive to physiologic concentrations of IL-2 represents a potential improvement over existing approaches. We have determined whether in vivo administration of monoclonal antibodies (mAbs) directed at the T-cell surface protein CD3 induces T-cell responsiveness to IL-2, stimulates cytolytic molecular programs of natural killer cells and cytotoxic T cells, and induces tumor regression. These hypotheses were explored in a murine hepatic MCA-102 fibrosarcoma model. We report that in vivo administration of anti-CD3 mAbs plus IL-2 results in intrahepatic expression of mRNA-encoding perforin, cytotoxic T-cell-specific serine esterase, and tumor necrosis factor α. Anti-CD3 mAbs alone or IL-2 alone failed to induce or induced minimal expression of these molecular mediators of cytotoxicity. The anti-CD3 mAbs plus IL-2 regimen also resulted in a significantly smaller number of hepatic metastases and a significantly longer survival time of tumor-bearing mice, compared to treatment with anti- CD3 mAbs alone or IL-2 alone. Our findings suggest that a regimen of anti- CD3 mAbs plus IL-2 is a more effective antitumor regimen compared with anti- CD3 mAbs alone or IL-2 alone and advance an alternative immunotherapy strategy of potential value for the treatment of cancer in humans.

AB - Adoptive cellular immunotherapy, infusions of interleukin 2 (IL-2) in conjunction with in vitro-activated killer cells, has brought new hope to patients with cancer. The broad application of this strategy, however, is constrained by the need for repeated leukapheresis and by the labor-intensive process of in vitro activation of cells. Also, current protocols generally use nonphysiological and toxic concentrations of IL-2. Identification of an in vivo stimulant that renders T cells responsive to physiologic concentrations of IL-2 represents a potential improvement over existing approaches. We have determined whether in vivo administration of monoclonal antibodies (mAbs) directed at the T-cell surface protein CD3 induces T-cell responsiveness to IL-2, stimulates cytolytic molecular programs of natural killer cells and cytotoxic T cells, and induces tumor regression. These hypotheses were explored in a murine hepatic MCA-102 fibrosarcoma model. We report that in vivo administration of anti-CD3 mAbs plus IL-2 results in intrahepatic expression of mRNA-encoding perforin, cytotoxic T-cell-specific serine esterase, and tumor necrosis factor α. Anti-CD3 mAbs alone or IL-2 alone failed to induce or induced minimal expression of these molecular mediators of cytotoxicity. The anti-CD3 mAbs plus IL-2 regimen also resulted in a significantly smaller number of hepatic metastases and a significantly longer survival time of tumor-bearing mice, compared to treatment with anti- CD3 mAbs alone or IL-2 alone. Our findings suggest that a regimen of anti- CD3 mAbs plus IL-2 is a more effective antitumor regimen compared with anti- CD3 mAbs alone or IL-2 alone and advance an alternative immunotherapy strategy of potential value for the treatment of cancer in humans.

KW - antitumor efficacy

KW - perforin

KW - T-cell signaling

UR - http://www.scopus.com/inward/record.url?scp=0028021823&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028021823&partnerID=8YFLogxK

U2 - 10.1073/pnas.91.17.7889

DO - 10.1073/pnas.91.17.7889

M3 - Article

C2 - 8058730

AN - SCOPUS:0028021823

VL - 91

SP - 7889

EP - 7893

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 17

ER -